Free fatty acid receptor 4 activation protects against choroidal neovascularization in mice.
Age-related macular degeneration (AMD)
Free fatty acid receptor 4 (FFAR4)
IL-6
Laser-induced choroidal neovascularization (CNV)
NF-ĸb
Journal
Angiogenesis
ISSN: 1573-7209
Titre abrégé: Angiogenesis
Pays: Germany
ID NLM: 9814575
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
05
12
2019
accepted:
24
02
2020
pubmed:
7
3
2020
medline:
7
7
2021
entrez:
7
3
2020
Statut:
ppublish
Résumé
To examine whether free fatty acid receptor 4 (FFAR4) activation can protect against choroidal neovascularization (CNV), which is a common cause of blindness, and to elucidate the mechanism underlying the inhibition, we used the mouse model of laser-induced CNV to mimic angiogenic aspects of age-related macular degeneration (AMD). Laser-induced CNV was compared between groups treated with an FFAR4 agonist or vehicle, and between FFAR4 wild-type (Ffar4
Identifiants
pubmed: 32140799
doi: 10.1007/s10456-020-09717-x
pii: 10.1007/s10456-020-09717-x
pmc: PMC8627650
mid: NIHMS1756986
doi:
Substances chimiques
Cytokines
0
FFAR4 protein, mouse
0
NF-kappa B
0
Receptors, G-Protein-Coupled
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
385-394Subventions
Organisme : NEI NIH HHS
ID : R01 EY017017
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY030140
Pays : United States
Organisme : NIH HHS
ID : R01EY01717-13S1
Pays : United States
Organisme : NEI NIH HHS
ID : R01EY029238
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY030904
Pays : United States
Organisme : NEI NIH HHS
ID : R01EY030140
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY029238
Pays : United States
Organisme : NICHD NIH HHS
ID : U54 HD090255
Pays : United States
Organisme : NIH HHS
ID : R24EY024868
Pays : United States
Références
Mol Pharmacol. 2013 Nov;84(5):710-25
pubmed: 23979972
PLoS One. 2012;7(6):e40168
pubmed: 22768248
Ophthalmology. 2013 Dec;120(12):2630-2636
pubmed: 23830760
Ophthalmic Res. 2009;42(4):205-12
pubmed: 19672129
Lancet Glob Health. 2014 Feb;2(2):e106-16
pubmed: 25104651
Invest Ophthalmol Vis Sci. 2017 Aug 1;58(10):3862-3870
pubmed: 28763559
Ophthalmology. 2014 Jan;121(1):150-161
pubmed: 24084496
FASEB J. 2013 Dec;27(12):4987-97
pubmed: 24005906
Annu Rev Nutr. 2015;35:239-63
pubmed: 26185978
Exp Eye Res. 2012 Sep;102:1-9
pubmed: 22721721
Am J Pathol. 2011 May;178(5):2416-23
pubmed: 21514452
Nat Protoc. 2013 Nov;8(11):2197-211
pubmed: 24136346
Sci Rep. 2018 Sep 25;8(1):14318
pubmed: 30254287
Nature. 2012 Feb 19;483(7389):350-4
pubmed: 22343897
Nat Med. 2014 Aug;20(8):942-7
pubmed: 24997608
Am J Pathol. 2007 Jun;170(6):2149-58
pubmed: 17525280
Nat Med. 2016 Apr;22(4):439-45
pubmed: 26974308
N Engl J Med. 2006 Oct 5;355(14):1474-85
pubmed: 17021323
Mol Vis. 2012;18:574-80
pubmed: 22419849
J Cell Physiol. 2003 May;195(2):241-8
pubmed: 12652651
PLoS One. 2013 Jul 26;8(7):e69552
pubmed: 23922736
J Hepatol. 2014 Mar;60(3):625-32
pubmed: 24262133
Arch Ophthalmol. 2004 Apr;122(4):564-72
pubmed: 15078675
Invest Ophthalmol Vis Sci. 1999 Aug;40(9):1891-8
pubmed: 10440240
PLoS One. 2015 Jul 10;10(7):e0132643
pubmed: 26161975
Retina. 2009 Apr;29(4):523-9
pubmed: 19262441
Yakugaku Zasshi. 2019;139(9):1169-1175
pubmed: 31474633
Trends Pharmacol Sci. 2011 Sep;32(9):543-50
pubmed: 21663979
EMBO Mol Med. 2019 Oct;11(10):e10473
pubmed: 31486227
EBioMedicine. 2019 Jan;39:540-551
pubmed: 30578080
Graefes Arch Clin Exp Ophthalmol. 2007 Oct;245(10):1475-85
pubmed: 17406884
Biochem Pharmacol. 2016 Jun 15;110-111:1-15
pubmed: 26827942
Retina. 2008 Nov-Dec;28(10):1395-9
pubmed: 18827737
Trans Am Ophthalmol Soc. 1979;77:707-45
pubmed: 94717
PLoS One. 2014 Jun 09;9(6):e97957
pubmed: 24911523
EMBO Mol Med. 2018 Mar;10(3):
pubmed: 29343498
Nat Med. 2007 Jul;13(7):868-873
pubmed: 17589522
Cell. 2010 Sep 3;142(5):687-98
pubmed: 20813258
PLoS One. 2014 Feb 04;9(2):e88005
pubmed: 24505350
Trends Mol Med. 2007 Aug;13(8):345-52
pubmed: 17644433